Dirithromycin


Concise Prescribing Info
Indications/Uses
Susceptible infections.
Dosage/Direction for Use
Adult : PO 500 mg once daily.
Dosage Details
Oral
Pulmonary infections, Skin and soft tissue infections
Adult: 500 mg once daily as enteric-coated tablets.
Contraindications
Hypersensitivity. Patients who previously developed liver disorders while receiving the drug.
Special Precautions
Hepatic or renal impairment; prolongation of QT interval; porphyria; pregnancy; lactation.
Adverse Reactions
GI disturbances; hypersensitivity reactions; reversible hearing loss; cholestatic jaundice; CV effects; myasthenia-like syndrome; Stevens-Johnson syndrome; toxic epidermal necrolysis.
Drug Interactions
Drugs known to prolong QT interval; digoxin; oral contraceptives; cimetidine.
Potentially Fatal: Ventricular arrhythmias with astemizole, terfenadine and cisapride.
Lab Interference
May interfere with measurements of urinary catecholamines A-hydroxycorticosteroids. False elevation of serum AST values when measured colorimetrically.
Action
Description: Dirithromycin is a prodrug of erythromyclamine, which binds reversibly to 50s ribosomal subunit causing blockade of transpeptidation/translocation reactions, inhibition of protein synthesis and thus inhibition of cell growth. Spectrum of activity includes many gram-positive and some gram-negative bacteria, as well as mycoplasmas, spirochetes, chlamydias and rickettsias.
Pharmacokinetics:
Absorption: Readily absorbed after oral admin; undergoes rapid non-enzymatic hydrolysis to its active metabolite erythromycylamine. Bioavailability: About 10%.
Distribution: Widely distributed and tissue concentrations exceed those in plasma. Protein binding:15-30%.
Excretion: Largely excreted unchanged in the bile with only about 2% in the urine. Mean plasma half-life: About 8 hr.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Dirithromycin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in